Ph.D., Executive Chairman, Invitae Corporation
Randy Scott is Executive Chairman of Invitae Corporation (NYSE: NVTA), a leading genetic information company. Dr. Scott is also co-founder and Chairman of the Board for Genome Medical, a nationwide tele-genetics medical practice serving patients, physicians and hospital systems. Dr. Scott served as CEO of Invitae from 2012-2017 and previously founded Genomic Health (NASDAQ: GHDX) in 2000 where he served as Chairman and CEO for nine years and Executive Chairman for three years. Prior to Genomic Health Dr. Scott was a cofounder, Chief Scientific Officer and President at Incyte (NASDAQ: INCY), a genomic information company. Dr. Scott, an author of more than 40 scientific publications, 20 patents, and recipient of numerous awards, holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: Historically, genetic testing has only been available to a small number of qualified patients and high-risk families after serious disease has already been detected — largely because of cost and clinical utility considerations. However, family history can be a relatively poor indicator of risk for a variety of reasons and a growing body of clinical evidence suggests that serious Mendelian-inherited genetic conditions (of which there are over 4,000) are far more prevalent in the general population than previously appreciated. As comprehensive genetic testing becomes more affordable and accessible it will also become increasingly available and clinically actionable for healthy individuals in the primary care setting. The day in which we can test for all known inherited genetic conditions for a cost of a few hundred dollars is rapidly approaching and will forever change our approach to preventive medicine.